Rubius Therapeutics Inc (NASDAQ:RUBY) Insider Christopher L. Carpenter Sells 48,000 Shares

Rubius Therapeutics Inc (NASDAQ:RUBY) insider Christopher L. Carpenter sold 48,000 shares of Rubius Therapeutics stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $10.11, for a total transaction of $485,280.00.

Shares of RUBY stock opened at $10.30 on Friday. The company has a market capitalization of $825.97 million, a price-to-earnings ratio of -4.54 and a beta of 2.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 17.27 and a current ratio of 17.27. The company has a 50-day simple moving average of $10.41 and a 200 day simple moving average of $14.55. Rubius Therapeutics Inc has a 52 week low of $8.54 and a 52 week high of $24.49.

Rubius Therapeutics (NASDAQ:RUBY) last announced its earnings results on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.04). During the same period last year, the company earned ($3.33) EPS. Sell-side analysts forecast that Rubius Therapeutics Inc will post -2.02 EPS for the current year.



Several analysts recently commented on the stock. JPMorgan Chase & Co. reduced their target price on shares of Rubius Therapeutics from $27.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, August 29th. Zacks Investment Research raised shares of Rubius Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 24th. Guggenheim assumed coverage on shares of Rubius Therapeutics in a report on Thursday, May 30th. They set a “buy” rating and a $25.00 target price for the company. ValuEngine raised shares of Rubius Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, HC Wainwright assumed coverage on shares of Rubius Therapeutics in a report on Wednesday, June 26th. They set a “buy” rating and a $40.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Rubius Therapeutics has an average rating of “Buy” and an average target price of $23.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of RUBY. Bank of Montreal Can bought a new stake in Rubius Therapeutics in the 2nd quarter valued at about $46,000. Tower Research Capital LLC TRC bought a new stake in shares of Rubius Therapeutics during the 2nd quarter worth approximately $67,000. SG Americas Securities LLC bought a new stake in shares of Rubius Therapeutics during the 1st quarter worth approximately $117,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Rubius Therapeutics by 19,092.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,485 shares of the company’s stock worth $135,000 after acquiring an additional 7,446 shares during the period. Finally, UBS Asset Management Americas Inc. acquired a new position in Rubius Therapeutics during the 2nd quarter worth approximately $162,000. 97.74% of the stock is owned by hedge funds and other institutional investors.

Rubius Therapeutics Company Profile

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.